Sprint Bioscience AB 

€0.35
0
+€0.02+7.65% Today

Statistics

Day High
0.35
Day Low
0.35
52W High
0.35
52W Low
0.02
Volume
-
Avg. Volume
-
Mkt Cap
37.14M
P/E Ratio
2.79
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

44.25%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
33.91MRevenue
15.01MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5JA1.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN.ST
Mkt Cap2.96T
AstraZeneca competes in the pharmaceutical and biotechnology industry focusing on the discovery and development of drugs, similar to Sprint Bioscience.
Novartis
NVS
Mkt Cap297.35B
Novartis is a global healthcare company that operates in the same therapeutic areas as Sprint Bioscience, making them direct competitors in drug development.
Pfizer
PFE
Mkt Cap153.13B
Pfizer is involved in the development and manufacturing of health care products including innovative medicines and vaccines, overlapping with Sprint Bioscience's market.
Merck
MRK
Mkt Cap300.2B
Merck operates in the pharmaceutical industry, focusing on drug development and therapies, directly competing with Sprint Bioscience in the oncology and metabolic diseases sector.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas similar to those targeted by Sprint Bioscience, including cancer treatments.
AMGEN
AMGN
Mkt Cap189.22B
Amgen focuses on human therapeutics and operates in the same biotechnology sector as Sprint Bioscience, particularly in innovative drug development.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol-Myers Squibb is a global biopharmaceutical company whose areas of research include cancer, a key focus area for Sprint Bioscience, making them competitors.
Lilly(Eli) &
LLY
Mkt Cap840.84B
Eli Lilly and Company develops and markets pharmaceutical products for global markets, competing with Sprint Bioscience in the areas of drug discovery and oncology.
Roche
RHHBY
Mkt Cap322.3B
Roche Holding AG engages in the pharmaceuticals and diagnostics business, directly competing with Sprint Bioscience in the field of oncology research and drug development.
Sanofi
SNY
Mkt Cap113.88B
Sanofi operates globally in pharmaceuticals, focusing on therapeutic solutions similar to Sprint Bioscience, including treatments for chronic diseases and cancer.

About

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. The company was incorporated in 2009 and is based in Huddinge, Sweden.
Show more...
CEO
Mr. Johan Emilsson
Employees
30
Country
Sweden
ISIN
SE0006343745
WKN
000A14NY2

Listings

0 Comments

Share your thoughts

FAQ

What is Sprint Bioscience AB stock price today?
The current price of 5JA1.F is €0.35 EUR — it has increased by +7.65% in the past 24 hours. Watch Sprint Bioscience AB stock price performance more closely on the chart.
What is Sprint Bioscience AB stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sprint Bioscience AB stocks are traded under the ticker 5JA1.F.
Is Sprint Bioscience AB stock price growing?
5JA1.F stock has risen by +60.73% compared to the previous week, the month change is a +128.57% rise, over the last year Sprint Bioscience AB has showed a +551.85% increase.
What is Sprint Bioscience AB market cap?
Today Sprint Bioscience AB has the market capitalization of 37.14M
When is the next Sprint Bioscience AB earnings date?
Sprint Bioscience AB is going to release the next earnings report on May 13, 2026.
What is Sprint Bioscience AB revenue for the last year?
Sprint Bioscience AB revenue for the last year amounts to 33.91M EUR.
What is Sprint Bioscience AB net income for the last year?
5JA1.F net income for the last year is 15.01M EUR.
How many employees does Sprint Bioscience AB have?
As of April 15, 2026, the company has 30 employees.
In which sector is Sprint Bioscience AB located?
Sprint Bioscience AB operates in the Health & Wellness sector.
When did Sprint Bioscience AB complete a stock split?
The last stock split for Sprint Bioscience AB was on October 29, 2019 with a ratio of 15:14.
Where is Sprint Bioscience AB headquartered?
Sprint Bioscience AB is headquartered in Huddinge, Sweden.